KG
TEVA icon

Kilter Group’s Teva Pharmaceuticals TEVA Stock Holding History

Kilter Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39K Buy
100
+59
+144% +$1.97K ﹤0.01% 817
2026
Q1 		$1.24K Buy
41
+2
+5% +$64 ﹤0.01% 1161
2025
Q4 		$1.22K Hold
39
– – ﹤0.01% 994
2025
Q3 		$788 Buy
39
+13
+50% +$228 ﹤0.01% 952
2025
Q2 		$436 Buy
+26
New +$420 ﹤0.01% 1000

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Kilter Group's TEVA Position: Q2 2026 in Review

Kilter Group increased its Teva Pharmaceuticals (TEVA) stake by 144% in Q2 2026, buying an estimated $1.97K and bringing the position to 100 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

Kilter Group first reported a position in TEVA in Q2 2025 and has held it in 5 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Kilter Group held 100 shares of Teva Pharmaceuticals worth $3.39K as of Q2 2026.
  • Kilter Group bought 59 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.97K.
  • Teva Pharmaceuticals made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #817 holding.
  • Kilter Group first reported a position in Teva Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.